ArticleAdvanced biomedical research2025
Prevalence and Odds of Cognitive Impairment in Multiple Sclerosis Subtypes and Neuromyelitis Optica Spectrum Disorder: A Case-Control Study.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune demyelinating disorders, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), are caused by persistent inflammation and damage to the central nervous system. Cognitive impairment (CI) is a growing challenge in these diseases, underscoring the need for a thorough exploration of its prevalence and risk across various subtypes. This study aimed to assess the prevalence and odds of CI using the Symbol Digit Modalities Test (SDMT) in various MS subtypes and NMOSD. Materials and Methods: A case-control study involving 616 participants, including healthy controls (HC) and individuals with different MS subtypes (Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS)), clinically isolated syndrome (CIS), and NMOSD, was conducted. CI was defined as SDMT z-scores 1.5 standard deviations below the HC average. The chi-square test was used to assess the risk of CI. Results: The prevalence of CI varied across different groups: HC (10.7%), RRMS (33.8%), SPMS (71.3%), PPMS (62.8%), CIS (19.2%), and NMOSD (32.8%). Odds ratios (OR) for CI were significantly increased in RRMS (OR: 4.23, confidence interval (CI): 2.18-8.22, Conclusion: This study emphasizes a significantly increased risk of CI in MS subtypes and NMOSD compared to HC. Although no significant difference in CI risk was found between individuals with RRMS and NMOSD, those with progressive forms of MS exhibited notably higher risks of CI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.